XNA

DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

Retrieved on: 
Sunday, April 16, 2023
KRAS, Sanger, AACR, NGS, DNA sequencing, Cancer, Mutation, NSCLC, XNA, MRD, Real-time, Patient, CDX, American Association for Cancer Research, FDA, Medical imaging

PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.

Key Points: 
  • PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.
  • The presentations will focus on how XNA can be used to improve the assay sensitivity of different technology platforms such as Sanger sequencing, qPCR, and Next Generation Sequencing (NGS).
  • DiaCarta’s XNA technology has demonstrated improvements to the sensitivity of traditional Sanger sequencing to comparable sensitivity levels of NGS, with much broader clinical utility and lower cost.
  • The XNA-based Sanger sequencing and qPCR are used for sensitive companion diagnostics (CDx) assay development for identification of KRAS G12C mutation.

DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.

Retrieved on: 
Friday, October 14, 2022
Professional Services, Health, Genetics, Other Science, Finance, Science, Biotechnology, CLIA, Investment, Qi, CEO, Health, DNA, LLP, Solution, Business architecture, ISO, HHLA, Communication, LLC, Person, NYSE, Company, Industry, CCM, Domestication, HH, Liquid biopsy, FDA, Suite, New, Growth, Sponsor, Security (finance), Technology, U.S. Securities and Exchange Commission, Radiation, Prospectus, Name, Combination, Physician, Sale, Cayman Islands, SEC, Morgan, Lewis & Bockius, XNA, GMP, Genomics, Patient, IPO, Transaction, RNA, Business, York House, Colorectal cancer, Acquisition, Landmark, White & Case, Proxy, Forward-looking statement, Bank, Medical imaging, Financial adviser, Management

(DiaCarta or the Company), a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co. (NYSE: HHLA.U, HHLA, HHLA WS) (HH&L), a publicly traded special purpose acquisition company (SPAC), today announced that they entered into a definitive business combination agreement (the Business Combination Agreement) that is expected to result in DiaCarta becoming a publicly listed company (the Transaction or Business Combination).

Key Points: 
  • (DiaCarta or the Company), a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, and HH&L Acquisition Co. (NYSE: HHLA.U, HHLA, HHLA WS) (HH&L), a publicly traded special purpose acquisition company (SPAC), today announced that they entered into a definitive business combination agreement (the Business Combination Agreement) that is expected to result in DiaCarta becoming a publicly listed company (the Transaction or Business Combination).
  • Upon closing of the Transaction, the combined company will be listed on the New York Stock Exchange.
  • DiaCarta is a precision molecular diagnostics company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy.
  • Based in Pleasanton, California, the Company is ISO certified, GMP-compliant and offers CLIA certified laboratory services to its customers.

Global Molecular Diagnostics Market to Surpass US$ 35,500.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
Wednesday, July 20, 2022
DNA, National, NGS, Cdx, Siemens Healthineers, Agilent Technologies, Abbott Laboratories, CRADA, Oncology, MammaPrint, Development, Biomarker, Partnership, Cooperative research and development agreement, NTRK3, TSO, National Cancer Institute, US, NTRK2, NTRK1, S.A, Cancer, Adoption, CAGR, IVD, Illumina, Inc., Technology, Company, Patient, Breast cancer, Analysis, XNA, Becton, Dickinson and Company headquarters, NCI, Medical imaging, Fine chemical, EU, Illumina

SEATTLE, July 20, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 20, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Molecular Diagnostics Market:
    Increasing product launches by market players is expected to drive the global molecular diagnostics market over the forecast period.
  • Global molecular diagnostics market is expected to exhibit a CAGR of 11.6% during the forecast period due to increasing adoption of inorganic growth strategies such as agreements by market players.
  • Key players operating in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, Agilent Technologies, Inc., Meridian, Cepheid, and Beckman Coulter, Inc.

Global Molecular Diagnostics Market to Surpass US$ 35,500.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
Wednesday, July 20, 2022
DNA, National, NGS, Cdx, Siemens Healthineers, Agilent Technologies, Abbott Laboratories, CRADA, Oncology, MammaPrint, Development, Biomarker, Partnership, Cooperative research and development agreement, NTRK3, TSO, National Cancer Institute, US, NTRK2, NTRK1, S.A, Cancer, Adoption, CAGR, IVD, Illumina, Inc., Technology, Company, Patient, Breast cancer, Analysis, XNA, Becton, Dickinson and Company headquarters, NCI, Medical imaging, Fine chemical, EU, Illumina

SEATTLE, July 20, 2022 /PRNewswire/ --According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 20, 2022 /PRNewswire/ --According to Coherent Market Insights, the global molecular diagnostics market is estimated to be valued at US$ 14,772.2 million in 2022 and is expected to exhibit a CAGR of 11.6 % during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Molecular Diagnostics Market:
    Increasing product launches by market players is expected to drive the global molecular diagnostics market over the forecast period.
  • Global molecular diagnostics market is expected to exhibit a CAGR of 11.6% during the forecast period due to increasing adoption of inorganic growth strategies such as agreements by market players.
  • Key players operating in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, Agilent Technologies, Inc., Meridian, Cepheid, and Beckman Coulter, Inc.

Newly Released Demo Reveals How Stonehenge Technology Labs Empowers CPG Companies with Real-time Insights Across Multiple Channels

Retrieved on: 
Tuesday, July 19, 2022
Omni, CEO, CPG, European Woman Innovator of the Year, LinkedIn, Time, MeadWestvaco, Twitter, Software, Northwest Arkansas, Organization, Industry, Stock, Instagram, Fast Company, ERP, Software as a service, Online shopping, Facebook, XNA

BENTONVILLE, Ark., July 19, 2022 /PRNewswire-PRWeb/ -- Stonehenge Technology Labs, creator of the STOPWATCH™ unified commerce software, announced availability of a live STOPWATCH demo with founder and CEO Meagan Bowman, as well as an exciting new video which gives a first look at how STOPWATCH is moving CPG companies into the age of omni-commerce. The live demo illustrates precisely how the platform has been shaking up the CPG industry with improved, real-time decision-making, and going far beyond what traditional ERP and other legacy platforms have been able to deliver.

Key Points: 
  • And while existing platforms play around the edges, actionable insights, and visibility across multiple online retail channels, in real-time, has been elusive until now.
  • "Despite the availability of large, complex, and very expensive platforms, companies still struggle to synergize real-time sales and ship data beyond a single online selling platform," said Meagan Bowman, Founder and CEO of Stonehenge Technology Labs.
  • Delivering that capability has been the mission of Stonehenge Technology Labs.
  • In the demo, visitors will be able to see exactly how Stonehenge, and the STOPWATCH platform, is bucking the trends and the traditions of the CPG industry.

DiaCarta Expands Board Leadership with Industry Veteran

Retrieved on: 
Thursday, April 7, 2022
Company, Audit committee, Family, Neoplasm, CLIA, Astellas Pharma, Hoffmann-La Roche, Baruch College, Deloitte, Compliance, SEC, Professional Football Compensation Committee, Horizon, Risk management, Genomics, Sarbanes–Oxley Act, XNA, University of London, Health, Technology, Goal, Liquid biopsy, Real-time, City University, ISO, Housing, Communities and Local Government Committee, GMP, Accounting, Certified Public Accountant, FDA, Blood, Acquisition, Medical imaging

As the Chairman of the Audit Committee, Jack's inputs to our company's path forward will be essential," said Aiguo (Adam) Zhang, Ph.D., Founder and Chief Executive Officer of DiaCarta.

Key Points: 
  • As the Chairman of the Audit Committee, Jack's inputs to our company's path forward will be essential," said Aiguo (Adam) Zhang, Ph.D., Founder and Chief Executive Officer of DiaCarta.
  • "DiaCarta has a demonstrated leadership position in personalized diagnostics, translational genomics and clinical sample testing services in the United States and China.
  • Mr. Kaye was selected to participate on several dissident board slates which included the Astellas, Inc./OSI, Roche Pharmaceuticals, Inc./Illumina, and the Horizon, Inc./Depomed M&A transactions.
  • DiaCarta is a molecular diagnostics company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy.

DiaCarta's Multivariant COVID-19 Test Accurately Detects the Omicron Variant

Retrieved on: 
Tuesday, November 30, 2021
GMP, Senior, World Health Organization, CEO, Emergency Use Authorization, Technology, WHO, World, Severe acute respiratory syndrome coronavirus 2, Blood, COVID-19, Liquid biopsy, COVID 19, Sequencing, Omicron, DNA, US, Health, Real-time, ISO, Neoplasm, FDA, CDC, XNA, DNA sequencing, CLIA, Commercial Operating System (COS), Concern, COVID, Vaccine

Last week, the World Health Organization (WHO) classifieda new SARS-CoV-2 variant, the B.1.1.529,as a Variant of Concern andclassified it theOmicron variant.

Key Points: 
  • Last week, the World Health Organization (WHO) classifieda new SARS-CoV-2 variant, the B.1.1.529,as a Variant of Concern andclassified it theOmicron variant.
  • Since the identification of the Omicron variant in Botswana last week, it was subsequently detected in South Africa with confirmed cases nearing 100 and rising.
  • As the Omicron variant mutations are similar to those in the Delta variant, the expectation is that it will transmit rapidly across the world.
  • Using this technology, the company has developed its highly sensitive, early detection ColoScape Colorectal Cancer test using blood.

Aptamers Market by Product Type, Technology, Application, End-users and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 17, 2021
Biotechnology, Pharmaceutical, Health, Cros, Growth, Aptamer, Medication, CAGR, Awareness, Cancer, Prevalence, USD, Therapy, DNA, Research, R, Conditional sentence, RNA, Biotechnology, Antibody, SELEX, XNA, Academy, Drug discovery, Fine chemical, Airline

The aptamers market is valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.

Key Points: 
  • The aptamers market is valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.
  • The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies.
  • Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications.
  • The aptamers market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

$28+ Billion Worldwide Synthetic Biology Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 10, 2021
Biotechnology, General Health, Health, Benchmark, XNA, University, Cancer, Ecosystem, Biofuel, World Economic Forum, Guanine, CAGR, Gene, Technology, AGCT, Coronavirus, Microfluidics, Growth, Investment, COVID-19, Metabolic engineering, Human, Synthetic biology, Genome, Genetic engineering, Allergy, Create, Enzyme, Toxicity, University of Washington, Adenine, DNA, Nature Research, Risk, Epidemic, Oligonucleotide, Microsoft, Animal, Pharmaceutical industry, Marketing, Fine chemical, Computer data storage

The "Synthetic Biology Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Synthetic Biology Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global synthetic biology market.
  • The report focuses on the synthetic biology market which is experiencing strong growth.
  • The global synthetic biology market is expected to grow from $8.64 billion in 2020 to $10.07 billion in 2021 at a compound annual growth rate (CAGR) of 16.6%.

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study

Retrieved on: 
Monday, October 11, 2021
Forward-looking statement, Institute of Liver and Biliary Sciences, Degenerative disease, Pharmacokinetics, ASO, Hepatitis, Therapy, CAMS, SAN, CHB, MB, COVID-19, Sirna, Drug development, GLOBE, MBA, N-Acetylgalactosamine, Liver disease, Safety, Viral hepatitis, PK, XNA, Doctor of Philosophy, Terminology, U.S. Securities and Exchange Commission, Asos, Private Securities Litigation Reform Act, Hope, RNA, Security (finance), Fatty liver disease, HBsAg, Patient, Nasdaq, NASH, Pharmaceutical industry, Vaccine

The trial is evaluating ALG-020572, a proprietary antisense oligonucleotide (ASO) therapeutic candidate that is designed to reduce circulating HBsAg (Hepatitis B surface antigen) levels.

Key Points: 
  • The trial is evaluating ALG-020572, a proprietary antisense oligonucleotide (ASO) therapeutic candidate that is designed to reduce circulating HBsAg (Hepatitis B surface antigen) levels.
  • Professor Ed Gane, MB ChB, Principal Investigator for the ALG-020572-401 study, added, I believe that reducing HBsAg levels is an essential step in achieving functional cure.
  • In Part 1, it will evaluate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) doses of ALG-020572 in healthy volunteers.
  • The portfolio also includesS-antigen Transport-inhibiting Oligonucleotide Polymer (STOPSTM) molecules, capsid assembly modulators (CAMs), and small interfering RNA (siRNA) drug candidates.